Standout Papers

Dapagliflozin in Patients with Chronic Kid... 2012 2026 2016 2021 2.8k
  1. Dapagliflozin in Patients with Chronic Kidney Disease (2020)
    Hiddo J.L. Heerspink, Bergur V. Stefánsson et al. New England Journal of Medicine
  2. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018)
    Melanie J. Davies, David A. D’Alessio et al. Diabetes Care
  3. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (2020)
    George L. Bakris, Rajiv Agarwal et al. New England Journal of Medicine
  4. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018)
    Melanie J. Davies, David A. D’Alessio et al. Diabetologia
  5. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis (2012)
    Caroline S. Fox, Kunihiro Matsushita et al. The Lancet
  6. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2020)
    Peter Rossing et al. Kidney International
  7. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022)
    Melanie J. Davies, Vanita R. Aroda et al. Diabetes Care
  8. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019)
    John B. Buse, Deborah J. Wexler et al. Diabetes Care
  9. Diabetic kidney disease (2015)
    Merlin C. Thomas, Michael Brownlee et al. Nature Reviews Disease Primers
  10. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022)
    Ian H. de Boer, Peter Rossing et al. Kidney International
  11. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (2024)
    Vlado Perkovic, Katherine R. Tuttle et al. New England Journal of Medicine
  12. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2021)
    Rajiv Agarwal, Gerasimos Filippatos et al. European Heart Journal
  13. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022)
    Melanie J. Davies, Vanita R. Aroda et al. Diabetologia
  14. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy (2015)
    George L. Bakris, Rajiv Agarwal et al. JAMA
  15. Diabetes and Hypertension: A Position Statement by the American Diabetes Association (2017)
    Ian H. de Boer, Sripal Bangalore et al. Diabetes Care
  16. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019)
    John B. Buse, Deborah J. Wexler et al. Diabetologia
  17. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial (2020)
    David C. Wheeler, Bergur V. Stefánsson et al. The Lancet Diabetes & Endocrinology
  18. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022)
    Ian H. de Boer, Kamlesh Khunti et al. Diabetes Care
  19. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial (2016)
    Peter Gæde, Jens Oellgaard et al. Diabetologia
  20. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021)
    David C. Wheeler, Robert D. Toto et al. Kidney International
  21. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022)
    Ian H. de Boer, Kamlesh Khunti et al. Kidney International
  22. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021)
    Ahmed M. Shaman, Stephen C. Bain et al. Circulation
  23. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease (2023)
    Peter Rossing, Florian M.M. Baeres et al. Nephrology Dialysis Transplantation
  24. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024)
    Johannes F.E. Mann, Peter Rossing et al. Nature Medicine
  25. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2024)
    Sunil V. Badve, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology
  26. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial (2024)
    Richard E. Pratley, Katherine R. Tuttle et al. Journal of the American College of Cardiology
  27. Combination therapy for kidney disease in people with diabetes mellitus (2024)
    Daniël H. van Raalte, Petter Bjornstad et al. Nature Reviews Nephrology
  28. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (2025)
    Rajiv Agarwal, Jennifer B. Green et al. New England Journal of Medicine

Immediate Impact

110 standout
Sub-graph 1 of 12

Citing Papers

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
2024 Standout
27 intermediate papers

Works of Peter Rossing being referenced

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2024 Standout
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
2023 Standout
and 28 more

Author Peers

Author Last Decade Papers Cites
Peter Rossing 22306 10480 10797 737 39.4k
Mark E. Cooper 17386 12490 12906 506 47.5k
Dick de Zeeuw 18996 18627 19532 818 51.7k
Christoph Wanner 17206 8088 13557 706 44.5k
Hiddo J.L. Heerspink 15519 6359 10487 583 27.7k
Eberhard Ritz 9208 13530 19039 926 43.6k
Vlado Perkovic 15353 7799 8477 398 29.1k
Johannes F.E. Mann 13170 10175 8974 275 28.7k
George L. Bakris 24604 34537 11719 836 66.0k
James R. Sowers 14251 15126 3247 681 41.2k
Elizabeth Selvin 11516 7730 4733 507 31.6k

All Works

Loading papers...

Rankless by CCL
2026